Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients

被引:30
作者
Sun, Yan [1 ,2 ]
Yu, Xinmin [1 ,2 ]
Shi, Xun [1 ,2 ]
Hong, Wei [1 ,2 ]
Zhao, Jun [1 ,2 ]
Shi, Lei [1 ,2 ]
机构
[1] Key Lab Diag & Treatment Technol Thorac Oncol, Hangzhou 310022, Zhejiang, Peoples R China
[2] Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou 310022, Zhejiang, Peoples R China
关键词
Lung adenocarcinoma; IASLC/ATS/ERS classification; Stage IB; Prognosis; EGFR mutation; IASLC/ATS/ERS CLASSIFICATION; INTERNATIONAL ASSOCIATION; PROGNOSTIC VALUE; CHINESE PATIENTS; CANCER; GEFITINIB;
D O I
10.1186/1477-7819-12-148
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: A new lung adenocarcinoma classification proposed by the International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society (IASLC/ATS/ERS) has recently been published. This study aimed to investigate the utility of the new histological classification for identifying the prognostic subtypes of adenocarcinomas in stage IB patients. Correlations between the classification and the presence of epidermal growth factor receptor (EGFR) mutation status was also studied. Methods: One hundred and thirty-six patients with stage IB lung adenocarcinoma operated on in Zhejiang Cancer Hospital were identified between 2002 and 2011. Patients overall survival and disease-free survival were calculated using Kaplan-Meier and Cox regression analyses. EGFR mutations were detected using the amplification refractory mutation system. Results: A total of 136 cases were included in current study, of which 38 were papillary predominant, 39 were acinar predominant, 22 were micropapillary predominant, 21 were lepidic predominant subtypes, 14 were solid predominant, and 2 were variants of invasive adenocarcinoma. Patients with micropapillary- and solid-predominant tumors had the lowest five-year disease-free survival (28.4 and 36.7%, respectively). Univariate and multivariate analysis showed that the micropapillary-predominant subtype was an independent predictor of disease-free survival (P = 0.0041 and 0.048, respectively), but not overall survival (P = 0.175 and 0.214, respectively). EGFR mutations were significantly associated with the micropapillary-predominant subtype patients (P = 0.0026). The EGFR mutation frequency is lower in the solid-predominant subtype than other subtypes (P = 0.0508). Conclusions: The predominant subtype in the primary tumor was associated with prognosis in resected stage IB lung adenocarcinoma. The EGFR mutation frequency of micropapillary-predominant subtype is higher than other subtypes.
引用
收藏
页数:9
相关论文
共 18 条
[1]   Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients-A single institution retrospective study of 292 lung adenocarcinoma [J].
Gu, Jie ;
Lu, Chunlai ;
Guo, Jing ;
Chen, Lingli ;
Chu, Yiwei ;
Ji, Yuan ;
Ge, Di .
JOURNAL OF SURGICAL ONCOLOGY, 2013, 107 (05) :474-480
[2]   Prognostic Value of the New International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Lung Adenocarcinoma Classification on Death and Recurrence in Completely Resected Stage I Lung Adenocarcinoma [J].
Hung, Jung-Jyh ;
Jeng, Wen-Juei ;
Chou, Teh-Ying ;
Hsu, Wen-Hu ;
Wu, Kou-Juey ;
Huang, Biing-Shiun ;
Wu, Yu-Chung .
ANNALS OF SURGERY, 2013, 258 (06) :1079-1086
[3]   Analysis of the T Descriptors and Other Prognosis Factors in Pathologic Stage I Non-small Cell Lung Cancer in China [J].
Li, Ziming ;
Yu, Yongfeng ;
Lu, Jiade ;
Luo, Qinquan ;
Wu, Chunxiao ;
Liao, Meilin ;
Zheng, Ying ;
ai, Xinghao ;
Gu, Lingping ;
Lu, Shun .
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (06) :702-709
[4]   Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].
Lynch, TJ ;
Bell, DW ;
Sordella, R ;
Gurubhagavatula, S ;
Okimoto, RA ;
Brannigan, BW ;
Harris, PL ;
Haserlat, SM ;
Supko, JG ;
Haluska, FG ;
Louis, DN ;
Christiani, DC ;
Settleman, J ;
Haber, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139
[5]   Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. [J].
Maemondo, Makoto ;
Inoue, Akira ;
Kobayashi, Kunihiko ;
Sugawara, Shunichi ;
Oizumi, Satoshi ;
Isobe, Hiroshi ;
Gemma, Akihiko ;
Harada, Masao ;
Yoshizawa, Hirohisa ;
Kinoshita, Ichiro ;
Fujita, Yuka ;
Okinaga, Shoji ;
Hirano, Haruto ;
Yoshimori, Kozo ;
Harada, Toshiyuki ;
Ogura, Takashi ;
Ando, Masahiro ;
Miyazawa, Hitoshi ;
Tanaka, Tomoaki ;
Saijo, Yasuo ;
Hagiwara, Koichi ;
Morita, Satoshi ;
Nukiwa, Toshihiro .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (25) :2380-2388
[6]   Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial [J].
Mitsudomi, Tetsuya ;
Morita, Satoshi ;
Yatabe, Yasushi ;
Negoro, Shunichi ;
Okamoto, Isamu ;
Tsurutani, Junji ;
Seto, Takashi ;
Satouchi, Miyako ;
Tada, Hirohito ;
Hirashima, Tomonori ;
Asami, Kazuhiro ;
Katakami, Nobuyuki ;
Takada, Minoru ;
Yoshioka, Hiroshige ;
Shibata, Kazuhiko ;
Kudoh, Shinzoh ;
Shimizu, Eiji ;
Saito, Hiroshi ;
Toyooka, Shinichi ;
Nakagawa, Kazuhiko ;
Fukuoka, Masahiro .
LANCET ONCOLOGY, 2010, 11 (02) :121-128
[7]   Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. [J].
Mok, Tony S. ;
Wu, Yi-Long ;
Thongprasert, Sumitra ;
Yang, Chih-Hsin ;
Chu, Da-Tong ;
Saijo, Nagahiro ;
Sunpaweravong, Patrapim ;
Han, Baohui ;
Margono, Benjamin ;
Ichinose, Yukito ;
Nishiwaki, Yutaka ;
Ohe, Yuichiro ;
Yang, Jin-Ji ;
Chewaskulyong, Busyamas ;
Jiang, Haiyi ;
Duffield, Emma L. ;
Watkins, Claire L. ;
Armour, Alison A. ;
Fukuoka, Masahiro .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) :947-957
[8]   Correlation of Mutation Status and Survival with Predominant Histologic Subtype According to the New IASLC/ATS/ERS Lung Adenocarcinoma Classification in Stage III (N2) Patients [J].
Russell, Prudence A. ;
Barnett, Stephen A. ;
Walkiewicz, Marzena ;
Wainer, Zoe ;
Conron, Matthew ;
Wright, Gavin M. ;
Gooi, Julian ;
Knight, Simon ;
Wynne, Rochelle ;
Liew, Danny ;
John, Thomas .
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (04) :461-468
[9]   Erlotinib in previously treated non-small-cell lung cancer [J].
Shepherd, FA ;
Pereira, JR ;
Ciuleanu, T ;
Tan, EH ;
Hirsh, V ;
Thongprasert, S ;
Campos, D ;
Maoleekoonpiroj, S ;
Smylie, M ;
Martins, R ;
van Kooten, M ;
Dediu, M ;
Findlay, B ;
Tu, DS ;
Johnston, D ;
Bezjak, A ;
Clark, G ;
Santabárbara, P ;
Seymour, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) :123-132
[10]   Histopathologic Characteristics of Lung Adenocarcinomas With Epidermal Growth Factor Receptor Mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Lung Adenocarcinoma Classification [J].
Shim, Hyo Sup ;
Lee, Da Hye ;
Park, Eun Ju ;
Kim, Se Hoon .
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2011, 135 (10) :1329-1334